Erika Hamilton
Medical oncologist and researcher at the Sarah Cannon Research Institute with expertise in breast cancer and antibody-drug conjugates, offering clinical perspectives on toxicity management and sequencing of ADCs.
Top 3 podcasts with Erika Hamilton
Ranked by the Snipd community
Nov 20, 2025 • 59min
HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Dr. Erika Hamilton, a medical oncologist at Sarah Cannon Research Institute, dives into the cutting-edge world of PROTAC estrogen receptor degraders for HR-positive metastatic breast cancer. She breaks down the differences between PROTACs and traditional therapies like SERDs, detailing their unique mechanisms and resistance advantages. The conversation highlights clinical trial data, tolerability issues, and the importance of precise biomarker testing. Erika also shares insights on future applications and the evolving landscape of treatment strategies for this challenging disease.
Sep 1, 2025 • 16min
Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Erika Hamilton, a medical oncologist and ADC researcher, offers clinical perspectives on TROP2-directed therapies. She discusses distinct toxicities of different ADCs and practical management tactics. Conversation covers ILD vigilance, mucositis and steroid mouthwash, prolonged antiemetic needs, eye care, PRIMED neutropenia prevention, CNS activity of datopotamab, and challenges in sequencing ADCs.
Jun 20, 2025 • 22min
ASCO 2025 - Breast Cancer Highlights: INAVO120, SERENA-6, VERITAC-2, DESTINY-Breast09, ASCENT-04
Join Dr. Erika Hamilton, a medical oncologist from the Sarah Cannon Research Institute, as she shares her expertise on groundbreaking breast cancer research from ASCO 2025. The discussion dives into the INAVO120 trial's survival benefits for specific patient groups, the promising results of SERENA-6 using ctDNA for better therapeutic decisions, and the significant progress shown in DESTINY-Breast09 and ASCENT-04 for treating advanced HER2-positive and triple-negative breast cancers. Explore the future of cancer treatment with these practice-changing insights!
